SOPHiA GENETICS CMO sells 7,393 shares for taxes

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu sold 7,393 ordinary shares of the company on July 6, 2026 at a weighted average price of $5.1611 per share.

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu sold 7,393 ordinary shares of the company on July 6, 2026 at a weighted average price of $5.1611 per share. According to the disclosure, these open-market sales were made to satisfy tax withholding obligations from restricted stock units that vested on July 2 and July 3, 2026, and were executed under a pre-established Rule 10b5-1(c) trading plan, meaning they were not discretionary trades. After the sale, Menu directly holds 233,387 ordinary shares, indicating he maintains a substantial ongoing equity position in the company.

Insider Trade Summary 10b5-1

Net Seller: 7,393 shares

Net Sell 1 txn

Insider Menu Philippe

Role Chief Medical Officer

Sold 7,393 shs ($38K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	7,393	$5.1611	$38K

Holdings After Transaction: Ordinary Shares — 233,387 shares (Direct)

Footnotes (2)

1. F1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on July 2 and July 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.97 to $5.44, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 7,393 shares Weighted average sale price: $5.1611 per share Post-sale holdings: 233,387 shares +2 more

5 metrics

Shares sold 7,393 shares Open-market sale on July 6, 2026

Weighted average sale price $5.1611 per share Ordinary share sale on July 6, 2026

Post-sale holdings 233,387 shares Direct ownership after transaction

Sale price range $4.97–$5.44 per share Multiple transactions within this range

Net shares sold 7,393 shares Net-sell direction in transaction summary

Key Terms

Rule 10b5-1(c) trading plan, restricted stock units, weighted average price

3 terms

Rule 10b5-1(c) trading plan regulatory

"These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan"

A Rule 10b5-1(c) trading plan is a legally defined, pre-set schedule that lets company insiders automatically buy or sell stock at specified times or under set formulas when they are not in possession of undisclosed, sensitive information. Think of it like an automatic payment plan for trades: because the instructions are written in advance, trades under the plan help protect insiders from allegations of trading on secret information and give investors clearer expectations about when insiders will transact, which can affect liquidity and perceived transparency.

restricted stock units financial

"tax withholding obligations arising in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did SOPHiA GENETICS (SOPH) Chief Medical Officer sell in this Form 4 filing?

The Chief Medical Officer, Philippe Menu, sold 7,393 ordinary shares of SOPHiA GENETICS. The shares were sold in the open market at a weighted average price of $5.1611 per share, as disclosed in the insider trading report filed with regulators.

Why did SOPH’s Chief Medical Officer sell 7,393 shares of SOPHiA GENETICS stock?

The 7,393 shares were sold to satisfy tax withholding obligations linked to vesting restricted stock units. The filing explains these sales were specifically to cover taxes due on RSUs that vested on July 2 and July 3, 2026.

Was the SOPHiA GENETICS (SOPH) insider sale by Philippe Menu a discretionary trade?

No, the sale was not discretionary. The filing states the transactions were executed under a pre-established Rule 10b5-1(c) trading plan, which automatically schedules trades in advance, reducing the insider’s day-to-day control over timing and execution.

What price did the SOPHiA GENETICS (SOPH) insider receive for the sold shares?

The reported price is a weighted average of $5.1611 per share. Footnotes note the 7,393 shares were sold in multiple trades at prices ranging from $4.97 to $5.44 per share, inclusive, across those open-market transactions.

How many SOPHiA GENETICS (SOPH) shares does the Chief Medical Officer still own after this sale?

After completing the tax-related sale, Philippe Menu directly holds 233,387 ordinary shares. This figure comes from the post-transaction ownership column in the Form 4 and shows his remaining equity stake following the reported transactions.

What is the significance of the Rule 10b5-1(c) plan mentioned in the SOPH insider filing?

The Rule 10b5-1(c) plan indicates trades were pre-arranged according to a written trading program. Such plans are designed to allow insiders to sell shares on a preset schedule, helping separate routine liquidity or tax transactions from opportunistic trading decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2026 - 04:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Menu Philippe

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	07/06/2026		S		7,393(1)	D	$5.1611(2)	233,387	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on July 2 and July 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.97 to $5.44, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Philippe Menu	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)